- Company
- Handok has domestic copyright of Exelon & Trileptal
- by An, Kyung-Jin Nov 27, 2019 06:42am
- Novartis Korea handed over copyrights of two neurology products including dementia medicine 'Exelon' to Handok pharmaceuticals. The intention is to organize copyrights for four medicines that were in charge of the department of neurology and concentrate sales marketing activities on the company's flagship products, including new products.
- Company
- Saxenda easily leads obesity market with KRW 32 bln by 3Q
- by Chon, Seung-Hyun Nov 27, 2019 06:41am
- Novo Nordisk’s Saxenda reaffirmed its unmatched leadership in obesity treatment market. Up to the third quarter this year, the treatment’s accumulated sales surpassed 30 billion won. And also Saxenda’s market share is stabilizing at over 30 percent. According to a pharmaceutical industry research firm IQVIA on Nov. 26, the overall obesity
- Opinion
- [Column]GPP can’t be off anymore
- by Jung, Heung-Jun Nov 27, 2019 06:40am
- GPP is a hot potato in the pharmaceutical society. It is unlikely that a executive of the pharmaceutical association with experience in business would completely deny the introduction of GPP. This is because the government and the public have been asking the pharmaceutical association for decades. But the drive is making slow progress. T
- Company
- Talking points on ‘Korea Passing’ in pharma industry
- by Eo, Yun-Ho Nov 27, 2019 06:36am
- The well-known expression ‘Korea Passing’, recently used to describe a phenomenon related to foreign affair discrepancies, does not mean the same in pharmaceutical industry. When it comes down to the Korean pharmaceutical industry, the expression does not indicate the U.S. and North Korea neglecting South Korea during the Korean peni
- Policy
- Clinical trial coverage on standard therapy and IND
- by Lee, Hye-Kyung Nov 26, 2019 10:52pm
- Insurance coverage would be granted on both investigational new drug and standard treatment simultaneously used in an anticancer treatment clinical trial. Health Insurance Review and Assessment Service (HIRA) presented a revised standard of healthcare insurance reimbursement on anticancer treatment in clinical trial on Nov. 4. From last
- Policy
- Ahn-gook’s first Galvus generic approved
- by Lee, Tak-Sun Nov 26, 2019 07:16am
- Ahn-gook Pharmaceutical (“Ahn-gook”) received an approval on the first generic version of a DPP-4 inhibiting antidiabetic treatment, Galvus (vildagliptin). The Ahn-gook’s approval got the industry’s attention as it challenged the original’s patent and shortened the patent’s term. On Nov. 22, Korean Ministry of Food and Drug Safety
- Policy
- 13 drugs containing Nizatidine were banned for sale
- by Lee, Hye-Kyung Nov 26, 2019 07:15am
- 13 gastrointestinal drugs containing 'Nizatidine' which had been covered by health insurance, now are not available on the 22nd. The MFDS and the HIRA said that on the 22nd, they took action that Nizatidine medicines are not prescribed or dispensed by hospitals, clinics or pharmacies, from the midnight, prescriptions and dispensing were blo
- InterView
- “Number one in Asia is what we are shooting for”
- by Kim, Jin-Gu Nov 26, 2019 07:15am
- “As far as dermatological treatment business goes, I think we have a shot at becoming the number one in Asian market”, Cho Yong-joon, CEO at Dongkoo Bio & Pharma (“Dongkoo”) commented. The CEO said ‘entering global market’ is the next long-term goal for the company while it gets closer to its 50th anniversary next year. CEO Cho was
- Policy
- MOHW lukewarm about Epilepsy Patient Support Bill
- by Lee, Jeong-Hwan Nov 26, 2019 07:12am
- ‘Epilepsy Patient Support Bill’ is at stake due to a dispute over feasibility of a bill specifically accommodating a certain disease. The National Assembly lawmakers and the government are contemplating on passing an individual bill for a disease as it could trigger other patients to demand bills for their disease, and cause confusion
- Policy
- A transition of power? Xofluza landed in Korea
- by Lee, Tak-Sun Nov 26, 2019 07:12am
- Flu medicines, which have been greatly improved in convenience, have landed in Korea. It is Roche's Xofluza (Baloxavir marboxil). It is expected to see the effects of flu treatment with only a single dose. The oseltamivir formulations, represented by conventional Tamiflu, had to be taken for 5 days. With Tamiflu's patent expiration in 2017
